Barbara M. Segal
University of Minnesota
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Barbara M. Segal.
Nature Genetics | 2013
Christopher J. Lessard; He Li; Indra Adrianto; John A. Ice; Astrid Rasmussen; Kiely Grundahl; Jennifer A. Kelly; Mikhail G. Dozmorov; Corinne Miceli-Richard; Simon Bowman; Susan Lester; Per Eriksson; Maija-Leena Eloranta; Johan G. Brun; Lasse G. Gøransson; Erna Harboe; Joel M. Guthridge; Kenneth M. Kaufman; Marika Kvarnström; Helmi Jazebi; Deborah S. Cunninghame Graham; Martha E. Grandits; Abu N. M. Nazmul-Hossain; Ketan Patel; Adam Adler; Jacen S. Maier-Moore; A. Darise Farris; Michael T. Brennan; James A. Lessard; James Chodosh
Sjögrens syndrome is a common autoimmune disease (affecting ∼0.7% of European Americans) that typically presents as keratoconjunctivitis sicca and xerostomia. Here we report results of a large-scale association study of Sjögrens syndrome. In addition to strong association within the human leukocyte antigen (HLA) region at 6p21 (Pmeta = 7.65 × 10−114), we establish associations with IRF5-TNPO3 (Pmeta = 2.73 × 10−19), STAT4 (Pmeta = 6.80 × 10−15), IL12A (Pmeta = 1.17 × 10−10), FAM167A-BLK (Pmeta = 4.97 × 10−10), DDX6-CXCR5 (Pmeta = 1.10 × 10−8) and TNIP1 (Pmeta = 3.30 × 10−8). We also observed suggestive associations (Pmeta < 5 × 10−5) with variants in 29 other regions, including TNFAIP3, PTTG1, PRDM1, DGKQ, FCGR2A, IRAK1BP1, ITSN2 and PHIP, among others. These results highlight the importance of genes that are involved in both innate and adaptive immunity in Sjögrens syndrome.
Genes and Immunity | 2009
Eshrat S. Emamian; Joanlise M. Leon; Christopher J. Lessard; Martha E. Grandits; Emily C. Baechler; Patrick M. Gaffney; Barbara M. Segal; Nelson L. Rhodus; Kathy L. Moser
Sjögrens syndrome (SS) is a common chronic autoimmune disease characterized by lymphocytic infiltration of exocrine glands. The affected cases commonly present with oral and ocular dryness, which is thought to be the result of inflammatory cell-mediated gland dysfunction. To identify important molecular pathways involved in SS, we used high-density microarrays to define global gene expression profiles in the peripheral blood. We first analyzed 21 SS cases and 23 controls, and identified a prominent pattern of overexpressed genes that are inducible by interferons (IFNs). These results were confirmed by evaluation of a second independent data set of 17 SS cases and 22 controls. Additional inflammatory and immune-related pathways with altered expression patterns in SS cases included B- and T-cell receptor, insulin-like growth factor-1, granulocyte macrophage-colony stimulating factor, peroxisome proliferator-activated receptor-α/retinoid X receptor-α and PI3/AKT signaling. Exploration of these data for relationships to clinical features of disease showed that expression levels for most interferon-inducible genes were positively correlated with titers of anti-Ro/SSA (P<0.001) and anti-La/SSB (P<0.001) autoantibodies. Diagnostic and therapeutic approaches targeting interferon-signaling pathway may prove most effective in the subset of SS cases that produce anti-Ro/SSA and anti-La/SSB autoantibodies. Our results strongly support innate and adaptive immune processes in the pathogenesis of SS, and provide numerous candidate disease markers for further study.
Health and Quality of Life Outcomes | 2009
Barbara M. Segal; Simon Bowman; Philip C. Fox; Frederick B. Vivino; Nandita Murukutla; Jeff Brodscholl; Sarika Ogale; Lachy McLean
ObjectiveTo assess the health related quality of life of patients with primary Sjögrens Syndrome (PSS) in a large US sample.MethodsQuestionnaires were mailed to 547 patients with a confirmed diagnosis of PSS (PhysR-PSS) and all active members of the Sjögrens Syndrome Foundation USA (SSF-PSS), half of whom identified a friend without PSS to also complete the survey.Results277 PhysR-PSS patients were compared to 606 controls. The mean age was 62 years in the PhysR-PSS group and 61 years in the control group. 90% in both groups were women. Time from first symptom to diagnosis of PSS was a mean of 7 years. Sicca related morbidity, fatigue severity, depression and pain (assessed by validated questionnaires, PROFAD-SSI, FACIT-F, CES-D, BPI) were significantly greater, and all eight SF-36 domains were significantly diminished, in patients compared to controls. Somatic fatigue was the dominant predictor of physical function and of general health. Depression was the dominant predictor of emotional well being. Health care utilization was higher in patients than controls, including out of pocket dental expenses (mean: PhysR-PSS =
Annals of the Rheumatic Diseases | 2014
Astrid Rasmussen; John A. Ice; He Li; Kiely Grundahl; Jennifer A. Kelly; Lida Radfar; Donald U. Stone; Kimberly S. Hefner; Juan-Manuel Anaya; Michael D. Rohrer; Rajaram Gopalakrishnan; Glen D. Houston; David M. Lewis; James Chodosh; John B. Harley; Pamela Hughes; Jacen S. Maier-Moore; Courtney G. Montgomery; Nelson L. Rhodus; A. Darise Farris; Barbara M. Segal; Roland Jonsson; Christopher J. Lessard; R. Hal Scofield; Kathy Moser Sivils
1473.3, controls =
American Journal of Human Genetics | 2014
Maureen D. Mayes; Lara Bossini-Castillo; Olga Y. Gorlova; José Martín; Xiaodong Zhou; Wei Chen; Shervin Assassi; Jun Ying; Filemon K. Tan; Frank C. Arnett; John D. Reveille; Sandra G. Guerra; María Teruel; F. Carmona; Peter K. Gregersen; Annette Lee; Elena López-Isac; Eguzkine Ochoa; Patricia Carreira; Carmen P. Simeon; I. Castellví; Miguel A. González-Gay; Alexandra Zhernakova; Leonid Padyukov; Marta E. Alarcón-Riquelme; Cisca Wijmenga; Matthew A. Brown; Lorenzo Beretta; Gabriela Riemekasten; Torsten Witte
503.6), dental visits (mean: PhysR-PSS = 4.0, controls = 2.3), current treatments (mean: PhysR-PSS = 6.6, controls = 2.5), and hospitalizations (53% PhysR-PSS, vs. 40% controls).ConclusionDiminished health quality and excess health costs are prevalent among PSS patients. Health experiences and functional impact of PSS is similar among US and European patients. Delayed diagnosis, sicca related morbidity, fatigue, pain and depression are substantial suggesting unmet health needs and the importance of earlier recognition of PSS.
Arthritis Care and Research | 2008
Barbara M. Segal; William Thomas; Tyson Rogers; Joanlise M. Leon; Pamela Hughes; Danielle Patel; Ketan Patel; Jill Novitzke; Michael D. Rohrer; Rajaram Gopalakrishnan; Sandra L. Myers; Abu N. M. Nazmul-Hossain; Eshrat S. Emamian; Andrew J.W. Huang; Nelson L. Rhodus; Kathy L. Moser
Abstract Objective To compare the performance of the American–European Consensus Group (AECG) and the newly proposed American College of Rheumatology (ACR) classification criteria for Sjögrens Syndrome (SS) in a well-characterised sicca cohort, given ongoing efforts to resolve discrepancies and weaknesses in the systems. Methods In a multidisciplinary clinic for the evaluation of sicca, we assessed features of salivary and lacrimal gland dysfunction and autoimmunity as defined by tests of both AECG and ACR criteria in 646 participants. Global gene expression profiles were compared in a subset of 180 participants. Results Application of the AECG and ACR criteria resulted in classification of 279 and 268 participants with SS, respectively. Both criteria were met by 244 participants (81%). In 26 of the 35 AECG+/ACR participants, the minor salivary gland biopsy focal score was ≥1 (74%), while nine had positive anti-Ro/La (26%). There were 24 AECG−/ACR+ who met ACR criteria mainly due to differences in the scoring of corneal staining. All patients with SS, regardless of classification, had similar gene expression profiles, which were distinct from the healthy controls. Conclusions The two sets of classification criteria yield concordant results in the majority of cases and gene expression profiling suggests that patients meeting either set of criteria are more similar to other SS participants than to healthy controls. Thus, there is no clear evidence for increased value of the new ACR criteria over the old AECG criteria from the clinical or biological perspective. It is our contention, supported by this report, that improvements in diagnostic acumen will require a more fundamental understanding of the pathogenic mechanisms than is at present available.
Journal of Neural Engineering | 2007
Apostolos P. Georgopoulos; Elissaios Karageorgiou; Arthur C. Leuthold; Scott M. Lewis; Joshua Lynch; Aurelio A. Alonso; Zaheer Aslam; Adam F. Carpenter; Angeliki Georgopoulos; Laura S. Hemmy; Ioannis G. Koutlas; Frederick J. P. Langheim; J. Riley McCarten; Susan E. McPherson; José V. Pardo; Patricia J. Pardo; Gareth Parry; Susan Rottunda; Barbara M. Segal; Scott R. Sponheim; John J. Stanwyck; Massoud Stephane; Joseph Westermeyer
In this study, 1,833 systemic sclerosis (SSc) cases and 3,466 controls were genotyped with the Immunochip array. Classical alleles, amino acid residues, and SNPs across the human leukocyte antigen (HLA) region were imputed and tested. These analyses resulted in a model composed of six polymorphic amino acid positions and seven SNPs that explained the observed significant associations in the region. In addition, a replication step comprising 4,017 SSc cases and 5,935 controls was carried out for several selected non-HLA variants, reaching a total of 5,850 cases and 9,401 controls of European ancestry. Following this strategy, we identified and validated three SSc risk loci, including DNASE1L3 at 3p14, the SCHIP1-IL12A locus at 3q25, and ATG5 at 6q21, as well as a suggested association of the TREH-DDX6 locus at 11q23. The associations of several previously reported SSc risk loci were validated and further refined, and the observed peak of association in PXK was related to DNASE1L3. Our study has increased the number of known genetic associations with SSc, provided further insight into the pleiotropic effects of shared autoimmune risk factors, and highlighted the power of dense mapping for detecting previously overlooked susceptibility loci.
Rheumatic Diseases Clinics of North America | 2008
Barbara M. Segal; Adam F. Carpenter; David Walk
OBJECTIVE To investigate the relationship of fatigue severity to other clinical features in primary Sjögrens syndrome (SS) and to identify factors contributing to the physical and mental aspects of fatigue. METHODS We identified 94 subjects who met the American-European Consensus Group criteria for the classification of primary SS. Fatigue was assessed with a visual analog scale, the Fatigue Severity Scale (FSS), and the Profile of Fatigue (ProF). Associations with fatigue were compared using multivariate regression. RESULTS Abnormal fatigue, defined as an FSS score >or=4, was present in 67% of the subjects. Pain, helplessness, and depression were the strongest predictors of fatigue according to the FSS and the somatic fatigue domain of the ProF (ProF-S), both with and without adjustment for physiologic and serologic characteristics. Depression was associated with higher levels of fatigue; however, the majority of subjects with abnormal fatigue were not depressed. Anti-Ro/SSA-positive subjects were no more likely to report fatigue than seronegative subjects. The regression models explained 62% of the variance in FSS and 78% of the variance in ProF-S scores. Mental fatigue was correlated with depression and helplessness, but the model predicted only 54% of the variance in mental fatigue scores. CONCLUSION Psychosocial variables are determinants of fatigue, but only partially account for it. Although fatigue is associated with depression, depression is not the primary cause of fatigue in primary SS. Investigation of the pathophysiologic correlates of physical and mental aspects of fatigue is needed to guide the development of more effective interventions.
Human Molecular Genetics | 2015
Leah C. Kottyan; Erin E. Zoller; Jessica Bene; Xiaoming Lu; Jennifer A. Kelly; Andrew Rupert; Christopher J. Lessard; Samuel E. Vaughn; Miranda C. Marion; Matthew T. Weirauch; Bahram Namjou; Adam Adler; Astrid Rasmussen; Stuart B. Glenn; Courtney G. Montgomery; Gideon M. Hirschfield; Gang Xie; Catalina Coltescu; Christopher I. Amos; He Li; John A. Ice; Swapan K. Nath; Xavier Mariette; Simon Bowman; Maureen Rischmueller; Susan Lester; Johan G. Brun; Lasse G. Gøransson; Erna Harboe; Roald Omdal
We report on a test to assess the dynamic brain function at high temporal resolution using magnetoencephalography (MEG). The essence of the test is the measurement of the dynamic synchronous neural interactions, an essential aspect of the brain function. MEG signals were recorded from 248 axial gradiometers while 142 human subjects fixated a spot of light for 45-60 s. After fitting an autoregressive integrative moving average (ARIMA) model and taking the stationary residuals, all pairwise, zero-lag, partial cross-correlations (PCC(ij)(0)) and their z-transforms (z(ij)(0)) between i and j sensors were calculated, providing estimates of the strength and sign (positive, negative) of direct synchronous coupling at 1 ms temporal resolution. We found that subsets of z(ij)(0) successfully classified individual subjects to their respective groups (multiple sclerosis, Alzheimers disease, schizophrenia, Sjögrens syndrome, chronic alcoholism, facial pain, healthy controls) and gave excellent external cross-validation results.
Acta Neurologica Scandinavica | 2012
Barbara M. Segal; Brian Pogatchnik; Erin Holker; Heshan Liu; Jeff A. Sloan; Nelson L. Rhodus; Kathy L. Moser
A wide range of central and peripheral nervous system disorders occur in patients with primary Sjögrens syndrome (pSS), although the true prevalence is an aspect which has been and remains controversial. Under-recognition of pSS and lack of consensus regarding criteria contribute to the uncertainty regarding the extent of neuropsychiatric involvement. A relatively high rate of affective and cognitive symptoms, as well as abnormal fatigue and poorly characterized pain, are features of pSS that contribute to diminishing health quality in the pSS population. This article describes the neurologic complications and controversies that surround the neurologic syndromes associated with pSS and reviews the current literature on potential immunopathogenetic mechanisms and therapy.